Sionna Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming the treatment landscape for cystic fibrosis (CF). The company focuses on developing innovative medicines that aim to normalize the function of the CFTR protein, with the goal of restoring CFTR function to near-normal levels for individuals living with CF. Sionna's approach involves stabilizing the nucleotide-binding domain 1 (NBD1) of the CFTR protein, which is crucial for improving clinical outcomes and quality of life for patients. With over a decade of research expertise from its co-founders, Sionna is advancing a pipeline of novel small molecules designed to correct defects caused by the F508del genetic mutation and is also developing complementary CFTR modulators to enhance the efficacy of its treatments.